Vertex Exec Sepp-Lorenzino Named Intellia Chief Scientific Officer

Laura Sepp-Lorenzino has joined Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]) as executive vice president and chief scientific officer. She comes to the Cambridge, MA, drug developer from Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]), where she was vice president, head of nucleic acid therapies, research leadership, as well as a member of the company’s external innovation team. Her experience also includes positions at Alynlam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) and Merck (NYSE: [[ticker:MRK]]). Intellia uses the CRISPR-Cas9 gene-editing system to develop new medicines.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.